drugset / Trial / NCT06140966
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
Phase 2
Recruiting
54 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NaSingle-groupOpen-labelTreatment
Summary
This study will assess whether the combination of daratumumab and carfilzomib-based Induction/Consolidation/Maintenance Therapy with ASCT improves the outcome of patients with ultra high-risk, newly diagnosed multiple myeloma
Timeline
- Start
- 2023-10-20
- Primary completion
- 2026-10-20
- Completion
- 2027-10-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | — | Subcutaneous |
| Subject | Carfilzomib | Other / unclassified | — | Intravenous |
| Subject | Cisplatin | Other / unclassified | — | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Subject | Daratumumab | Monoclonal antibody | — | Intravenous |
| Subject | Dexamethasone | Small molecule | — | Oral |
| Subject | Epirubicin | Small molecule | — | Intravenous |
| Subject | Etoposide | Small molecule | — | Intravenous |
| Subject | Lenalidomide | Other / unclassified | — | Oral |
| Subject | Melphalan | Small molecule | — | Intravenous |